6-K
Trinity Biotech PLC (TRIB)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
F O R M 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2022
TRINITY BIOTECH PLC
(Name of Registrant)
IDA Business Park
Bray, Co. Wicklow, Ireland
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279,333-195232 and 333-253070) and Registration Statements on Form F-3 (File Nos. 333-239701, 333-264992 and 333-267160).
EXPLANATORY NOTE
On September 30, 2022, Trinity Biotech plc. issued a press release announcing the results of its Annual General Meeting for 2022. A copy of the press release is filed herewith as Exhibit 99.1.
EXHIBIT INDEX
| Exhibit | Description |
|---|---|
| 99.1 | Trinity Biotech Announces<br> Results Of AGM |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TRINITY BIOTECH PLC | |
|---|---|
| By: | /s/ John Gillard |
| John Gillard | |
| Chief Financial Officer |
Date: September 30, 2022
Exhibit 99.1
Press Release dated September 30, 2022
| Contact: | Trinity Biotech plc | Lytham Partners, LLC |
|---|---|---|
| John Gillard | Joe Diaz | |
| (353)-1-2769800 | (1)-602-889-9700 | |
| E-mail: [email protected] |
Trinity Biotech Announces Results of AGM
DUBLIN, Ireland (September 30, 2022)…. Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the results of an Annual General Meeting (AGM).
AGM Results
On September 30, 2022 Trinity Biotech plc held an AGM of Shareholders at the Company’s headquarters at IDA Business Park, Bray, Co. Wicklow, Ireland.
At the AGM, the Company’s shareholders approved the following resolutions, as more fully set out in the Notice of AGM dated September 8, 2022:
| 1. | An ordinary resolution to increase the Company’s authorised share capital by the creation of an additional 600,000,000 A ordinary shares of US$0.0109 each. |
|---|---|
| 2. | An ordinary resolution to authorise the board of directors to reappoint Grant Thornton as the Company’s statutory auditors. |
| --- | --- |
| 3. | An ordinary resolution to authorise the board of directors to fix the statutory auditors’ remuneration. |
| --- | --- |
| 4. | Re-election of directors: |
| --- | --- |
| a. | An ordinary resolution to re-elect as a director Mr. Aris Kekedjian who retires by rotation and, being eligible, offers himself for re-election. |
| --- | --- |
| b. | An ordinary resolution to re-elect as a director Mr. Michael Sung Soo Kim who retires by rotation and, being eligible, offers himself for re-election. |
| --- | --- |
| c. | An ordinary resolution to re-elect as a director Mr. Seon Kyu Jeon who retires by rotation and, being eligible, offers himself for re-election. |
| --- | --- |
| 5. | An ordinary resolution to review the affairs of the Company and consider the financial statements of the Company for the year ended December 31, 2021 together with<br> the reports of the directors and statutory auditors thereon. |
| --- | --- |
| 6. | A special resolution to alter the Memorandum of Association of the Company. |
| --- | --- |
| 7. | A special resolution to adopt new Articles of Association of the Company to take account of certain changes to Irish company law resulting from the Companies Act 2014<br> (the "Act") and certain related developments. |
| --- | --- |
| 8. | A special resolution to renew the authority for the Company and/or any of its subsidiaries to purchase the Company's own shares and American Depositary Receipts<br> evidencing such shares ("ADRs") on NASDAQ within certain prescribed limits. |
| --- | --- |
Resolution 9, which sought to renew the price range at which any shares or ADRs held in treasury ("Treasury Shares") can be re-allotted other than on a securities exchange was not approved by the requisite majority of shareholders.
While a majority of proxy votes received on Resolution 9 were in favour of the resolution, an insufficient number of votes in favour of Resolution 9 were received in order to pass it as a special resolution.
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.